《新型冠状病毒肺炎诊疗方案（试行第九版）》于3月15日公布。

 

People with mild COVID-19 infections will be placed in centralized isolation¹, rather than in designated hospitals, according to the latest version of the national diagnosis² and treatment guideline released by the National Health Commission on Tuesday evening. The change is in response to the majority of cases involving the dominant³ Omicron strain being asymptomatic or only showing mild symptoms. As most do not need much treatment, admitting those with mild cases to designated hospitals will take up medical resources unnecessarily, the commission said in a statement explaining the new guideline.

国家卫健委发布的最新版诊疗方案称，轻型病例先实行集中隔离管理。这是根据各地反映的“奥密克戎变异毒株患者以无症状感染者和轻型病例为主，大多不需要过多治疗，全部收治到定点医院会占用大量医疗资源”等意见做出的调整。

 

To prevent cross infection, the guideline stressed that centralized quarantine facilities for mild cases should not take in overseas travelers and close contacts at the same time.

轻型病例相关集中隔离场所不能同时隔离入境人员、密切接触者等人群。

 

"Those with mild infections will be given therapies and monitored during isolation," it said. "If their condition worsens, they will be transferred to designated hospitals for further treatment."

轻型病例隔离管理期间应做好对症治疗和病情监测，如病情加重，应转至定点医院治疗。

 

Another change is a shortening of the isolation period for recovered patients.

新版诊疗方案还调整了康复患者的隔离时间。

 

Instead of 14 days in isolation, after being discharged from hospital, patients only need monitor their health condition at home for seven days.

将“出院后继续进行14天隔离管理和健康状况监测”修改为“解除隔离管理或出院后继续进行7天居家健康监测”。

 

In addition, two COVID-19 drugs approved recently by the national drug regulator have been added to the new guideline.They are Paxlovid, an antiviral medication developed by United States-based Pfizer, and a monoclonal antibody developed domestically.

另外，将国家药监局批准的两种特异性抗新冠病毒药物写入诊疗方案，即：美国辉瑞公司开发的抗病毒药——PF-07321332/利托那韦片（Paxlovid）和国产单克隆抗体（安巴韦单抗/罗米司韦单抗注射液）。

点击收听单词发音